BOT 1.33% 38.0¢ botanix pharmaceuticals ltd

Sofdra - Post approval royalties, costs and earnings, page-32

  1. 15,799 Posts.
    lightbulb Created with Sketch. 4077
    I'd say they want to see how it performs in the US market first. However, whilst earlier acquisitions do often happen, I've seen far more examples of big pharma companies waiting for post-approval before acquiring them. This includes drugs for much more debilitating conditions with little to zero alternative treatment options. Big pharma don't need to take that sort of risk to get a high return, they get the return by taking advantage of their economies of scale for commercialisation etc. So it doesn't make much sense for them to acquire before approval
    Last edited by TheAnalyst007: 29/04/24
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
38.0¢
Change
0.005(1.33%)
Mkt cap ! $687.8M
Open High Low Value Volume
37.5¢ 38.0¢ 36.0¢ $2.725M 7.415M

Buyers (Bids)

No. Vol. Price($)
3 70075 37.0¢
 

Sellers (Offers)

Price($) Vol. No.
38.0¢ 422900 17
View Market Depth
Last trade - 16.10pm 31/07/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.